Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Functional Technologies Corp FEBTF

Healthcare Biotechnology


GREY:FEBTF - Post by User

Functional Technologies Corp > Acrylamide in the news more and more.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1)
•••
Comment by MichaelD1on Oct 27, 2012 4:24am
146 Views
Post# 20530317

RE: Acrylamide in the news more and more.

RE: Acrylamide in the news more and more.

This is a pretty good Acrylamide link right here:

https://en.wikipedia.org/wiki/Acrylamide

I wonder if FEB is facing significant competition (from large players) for the niche it is targetting in the market?

That is the main risk I see here.

GLTA,

Michael D.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities